Exelixis, Inc. (NASDAQ:EXEL) Shares Acquired by Fifth Third Bancorp

Fifth Third Bancorp lifted its position in Exelixis, Inc. (NASDAQ:EXEL) by 16.1% in the 4th quarter, HoldingsChannel.com reports. The firm owned 3,231 shares of the biotechnology company’s stock after acquiring an additional 449 shares during the quarter. Fifth Third Bancorp’s holdings in Exelixis were worth $108,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently added to or reduced their stakes in the company. V Square Quantitative Management LLC purchased a new position in Exelixis in the third quarter valued at $30,000. USA Financial Formulas purchased a new stake in shares of Exelixis during the 4th quarter worth about $32,000. Brooklyn Investment Group acquired a new stake in shares of Exelixis during the 3rd quarter valued at about $42,000. UMB Bank n.a. increased its stake in shares of Exelixis by 68.4% in the 4th quarter. UMB Bank n.a. now owns 1,361 shares of the biotechnology company’s stock valued at $45,000 after purchasing an additional 553 shares in the last quarter. Finally, Capital Performance Advisors LLP acquired a new position in Exelixis in the 3rd quarter worth about $61,000. 85.27% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

EXEL has been the topic of several research analyst reports. Stephens reissued an “equal weight” rating and issued a $29.00 price objective on shares of Exelixis in a report on Monday, January 27th. Royal Bank of Canada reissued an “outperform” rating and issued a $34.00 price target on shares of Exelixis in a report on Wednesday, October 30th. Truist Financial increased their price objective on shares of Exelixis from $42.00 to $43.00 and gave the company a “buy” rating in a report on Monday, January 27th. UBS Group upped their price target on shares of Exelixis from $30.00 to $34.00 and gave the stock a “neutral” rating in a research report on Tuesday, January 28th. Finally, TD Cowen raised their price target on shares of Exelixis from $27.00 to $34.00 and gave the company a “buy” rating in a research note on Monday, October 21st. One analyst has rated the stock with a sell rating, seven have given a hold rating, eleven have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $36.06.

Exelixis Stock Performance

Exelixis stock opened at $33.15 on Friday. The company has a market capitalization of $9.47 billion, a price-to-earnings ratio of 21.25, a price-to-earnings-growth ratio of 0.72 and a beta of 0.53. The company’s 50 day simple moving average is $34.68 and its 200-day simple moving average is $30.13. Exelixis, Inc. has a 1 year low of $20.01 and a 1 year high of $37.59.

Insider Buying and Selling at Exelixis

In other Exelixis news, EVP Dana Aftab sold 96,986 shares of the business’s stock in a transaction dated Tuesday, November 5th. The shares were sold at an average price of $35.00, for a total transaction of $3,394,510.00. Following the sale, the executive vice president now directly owns 498,945 shares in the company, valued at $17,463,075. This represents a 16.27 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Jeffrey Hessekiel sold 60,000 shares of the firm’s stock in a transaction that occurred on Friday, November 29th. The shares were sold at an average price of $36.67, for a total transaction of $2,200,200.00. Following the completion of the transaction, the executive vice president now directly owns 486,059 shares of the company’s stock, valued at approximately $17,823,783.53. The trade was a 10.99 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 208,574 shares of company stock valued at $7,376,374 over the last quarter. 2.85% of the stock is owned by company insiders.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.